Dravet syndrome (DS), caused by loss-of-function variants in SCN1A, is classically aggravated by chronic sodium-channel blocker treatment, reflecting impaired interneuron excitability as a core disease mechanism. Cenobamate (CNB) challenges this: adult DS cases with substantial seizure reduction have been reported, while pediatric experience is mixed and includes a small cohort with no responders and frequent worsening. We report a 7-year-old girl with SCN1A-associated DS and severe developmenta